Rituximab in Systemic Sclerosis

• Status: Completed
• Trial end date: 2016-04-18

Summary

The purpose of this study is to determine whether rituximab is effective in the treatment of articular symptoms that occur in systemic sclerosis related polyarthritis

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Rituximab